Document is current
Any future updates will be listed below
-
Authors
Gonzalez-Cao, Maria https://orcid.org/0000-0003-3791-540X
Berciano-Guerrero, Miguel-Ángel
Muñoz-Couselo, Eva
Manzano, José Luis
Cerezuela-Fuentes, Pablo
Crespo, Guillermo
Soria, Ainara
de Miguel, Pablo Ayala
Gutiérrez Sanz, Lourdes
de la Rosa, Carlos Aguado
García Castaño, Almudena
Puértolas, Teresa
Espinosa, Enrique
Medina, Javier
Bellido, Lorena
Berrocal, Alfonso
Majem, Margarita
López Castro, Rafael
Fernandez, Luis Antonio
Garcia, Francisco
de la Borbolla, Maria Rodriguez
Martín Algarra, Salvador
Márquez-Rodas, Iván
-
Funding
Funding for this research was provided by:
spanish melanoma group
- License Information
-
More Information
Article History
Received: 17 June 2025
Accepted: 22 July 2025
First Online: 21 August 2025
Declarations
:
: The GEM1801 study was conducted following the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, and the Declaration of Helsinki, 1964; local laws; SAS order 3470/2009; and Organic Law 3/2018, of December 5, on the Protection of Personal Data and guarantee of digital rights.
: The study was reviewed and approved by the ethics committee of the Hospital Gregorio Marañón de Madridm (ref: 06/2018). All patients provided informed consent before inclusion.
: I-MR declares consulting fees Amgen, Astra Zeneca, BiolineRx, BMS, Celegene, GSK, Highlight Therapeutics, Immunocore, Merck Serono, MSD, Novartis, Pierre Fabre, Regeneron, Roche, Sanofi, Sun Pharma and support to attending meetings Amgen, BMS, GSK, Highlight Therapeutics, MSD, Novartis, Pierre Fabre, Roche, Sun Pharma. The rest of the authors declare no competing interests that could directly undermine, or be perceived to undermine the objectivity, integrity, and value of the publication, through a potential influence on the judgements and actions of authors regarding objective data presentation, analysis, and interpretation.
